Company intelligence / Profile preview
Biophytis
Paris, Ile-de-France, Francebiophytis.com ↗
- Ownership
- Public · BPTS
- Employees
- ~22
- Development stage
- Phase 2
01
Overview
Currently conducting Phase 2 clinical study (SARA) for sarcopenia in the US and Europe, and Phase 2-3 clinical study (COVA) for COVID-19 in Europe, Brazil, and the US. Recently postponed publication of annual financial statements for 2024 due to a €2.6 million refinancing operation announced in March 2025.
- Therapeutic areas
- OphthalmologyRare DiseasesMetabolic DisordersInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
AFM-Telethon (for development of BIO101 for DMD treatment)
Beyond the preview
Go deeper on Biophytis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biophytis.